OBJECTIVE: To examine the association between treatment adherence and indirect productivity costs within a cohort of commercially insured employees with bipolar disorder in the United States. METHODS: Adults diagnosed with bipolar disorder who had at least one prescription claim for a mood stabilizer or atypical antipsychotic, with 6 months prior and 12 months subsequent continuous medical and prescription coverage, were identified in the MarketScan research databases (2000-2005). Two-part multiple regression models estimated the association between adherence (medication possession ratio > or =0.80) and costs of absence, short-term disability, and workers' compensation. RESULTS: Of 1258 eligible employees, only 35.3% were adherent. Relative to adherent employees, nonadherent employees had higher adjusted indirect costs due to absence (+$771.41), short-term disability (+$284.72), and workers' compensation (+$360.63). CONCLUSIONS: Employers incur greater indirect costs when employees are not adherent to bipolar treatment.
OBJECTIVE: To examine the association between treatment adherence and indirect productivity costs within a cohort of commercially insured employees with bipolar disorder in the United States. METHODS: Adults diagnosed with bipolar disorder who had at least one prescription claim for a mood stabilizer or atypical antipsychotic, with 6 months prior and 12 months subsequent continuous medical and prescription coverage, were identified in the MarketScan research databases (2000-2005). Two-part multiple regression models estimated the association between adherence (medication possession ratio > or =0.80) and costs of absence, short-term disability, and workers' compensation. RESULTS: Of 1258 eligible employees, only 35.3% were adherent. Relative to adherent employees, nonadherent employees had higher adjusted indirect costs due to absence (+$771.41), short-term disability (+$284.72), and workers' compensation (+$360.63). CONCLUSIONS: Employers incur greater indirect costs when employees are not adherent to bipolar treatment.
Authors: Miguel A Boarati; Yuan-Pang Wang; Ana Paula Ferreira-Maia; Ana Rosa S Cavalcanti; Lee Fu-I Journal: Prim Care Companion CNS Disord Date: 2013-05-02
Authors: Susan J Wenze; Michael F Armey; Lauren M Weinstock; Brandon A Gaudiano; Ivan W Miller Journal: J Psychiatr Pract Date: 2016-11 Impact factor: 1.325
Authors: Rachelle Louise Cutler; Fernando Fernandez-Llimos; Michael Frommer; Charlie Benrimoj; Victoria Garcia-Cardenas Journal: BMJ Open Date: 2018-01-21 Impact factor: 2.692
Authors: Carlos De Las Cuevas; Jose de Leon; Wenceslao Peñate; Moisés Betancort Journal: Patient Prefer Adherence Date: 2017-03-28 Impact factor: 2.711
Authors: Tarek A Okasha; Doaa N Radwan; Hussien Elkholy; Heba M F M Hendawy; Eman M M E Shourab; Ramy R A Teama; Ahmed S Abdelgawad Journal: S Afr J Psychiatr Date: 2020-02-10 Impact factor: 1.550